特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
453761

米国の抗糖尿病薬市場の見通し

US Antidiabetics Drug Market Outlook 2022

出版日: | 発行: KuicK Research | ページ情報: 英文 120 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.14円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

米国の抗糖尿病薬市場の見通し
出版日: 2017年03月01日
発行: KuicK Research
ページ情報: 英文 120 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、米国の抗糖尿病薬市場について調査分析し、糖尿病の疫学、抗糖尿病薬市場の概要、主な上市製品、バイオシミラーインスリン、抗糖尿病薬市場の将来見通しなど、体系的な情報を提供しています。

第1章 抗糖尿病薬:糖尿病のレジメン

  • 糖尿病の前兆
  • 抗糖尿病薬とは

第2章 糖尿病の管理の歴史

  • 糖尿病からインスリンへ
  • 経口糖尿病治療薬への歴史的経路

第3章 糖尿病の治療

  • 糖尿病の非薬理学的アプローチ
  • 糖尿病の薬理学的アプローチ

第4章 抗糖尿病薬のカタログ

  • 抗糖尿病薬:経口薬
    • ビグアニド
    • チアゾリジンジオン (TZD)
    • スルホニル尿素
    • メグリチニド
    • α-グルコンシダーゼ阻害薬
    • DPP-4阻害薬
    • 胆汁酸抑制薬 (BAS)
    • ドーパミン作動薬-2

第5章 抗糖尿病薬:注射薬

  • インスリン
  • 非インスリン代替薬

第6章 米国の糖尿病の疫学

  • 1型・2型糖尿病の有病率
  • 1型・2型糖尿病関連の経済的負担

第7章 米国の抗糖尿病薬市場の概要

  • 米国の抗糖尿病薬 (注射薬) 市場の動向
  • 米国の抗糖尿病薬 (経口薬) 市場の動向
  • 糖尿病の推奨動向

第8章 米国:上市済みの主な抗糖尿病薬

第9章 米国のバイオシミラー市場

  • 概要
  • バイオシミラーインスリンの影響

第10章 米国の抗糖尿病薬市場力学

  • 促進要因
  • 主要課題

第11章 米国の抗糖尿病薬市場の将来見通し

第12章 競合情勢

  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Eli-Lilly
  • Johnson & Johnson
  • Merck
  • Novartis
  • Novo Nordisk
  • Sanofi
  • 武田薬品工業
目次

"US Antidiabetics Drug Market Outlook 2022" report gives clinical and non-clinical insight on trends associated with the development of Antidiabetics drug market in US. Report helps to identify the diabetes epidemiology ( Prevalence of Type 1 & 2 Diabetes) in the US market along with the associated economic burden and productivity loss.

Diabetes rates in the US have been increasing substantially. While the number of people with diabetes in the US continues to grow, the number of new cases has been declining since 2009, after decades of increases in new cases. Although the numbers are not growing dramatically each year, they are still alarmingly high. About 8.1 Million people with diabetes do not have knowledge that they have diabetes as prediabetes and type2 diabetes have few physical symptoms.

Diabetes mellitus being the most common chronic disease with high mortality, morbidity and costs, the number of people with diabetes is still increasing in US and other countries. More than 29 million Americans are living with diabetes, and 86 million are living with prediabetes. Though the benefits of tight control of blood glucose have been well recognized still the management of diabetes is complex which demands for the more efficient standardized antidiabetic regimen.

US insulin market occupies more than 70% of the overall insulin market and is expected to grow significantly until 2022 owing to the growing number of individuals with diabetes. Factors such as better accessibility to treatment therapies and favorable reimbursement programs will result in the high turnout of patients opting for diabetes treatment, which in turn will boost the market's growth prospects in this region.

The US Antidiabetics Drug Market has seen a resurgence of activity in recent years with promising new products, such as ultra-rapid-acting and liver targeted insulin analogues, and insulin plus GLP-1 combinations in late stage development. Earlier stage candidates include several oral formulations, as well as ultra-long acting insulin analogues. Some ultra-long acting insulin analogues in development have the potential to greatly reduce the dosing frequency to just once weekly for basal insulin needs, as opposed to once daily.

In addition, the prospect of promising drugs in the pipeline, along with increasing awareness, is expected to contribute to the market's growth during the forecast period. The market is dominated by three key players: Eli Lilly, Novo Nordisk, and Sanofi. Novo Nordisk is the major vendor in the global insulin market. The largest product wise market revenue was generated by Lantus, which is marketed by Sanofi.

"US Antidiabetics Drug Market Outlook 2022" report highlights:

  • US Diabetes Epidemiology
  • US Antidiabetics Market Overview
  • Key Marketed Antidiabetic Drugs in US
  • US Biosimilar Insulin Market
  • US Antidiabetics Drug Market Future Prospects

Table of Contents

1. Antidiabetics: Regimen for Diabetes Mellitus

  • 1.1 Prologue Towards Diabetes
  • 1.2 Preface to Antidiabetics

2. Antiquity of Managing Diabetes Mellitus

  • 2.1 Trajectory from Diabetes to Insulin
  • 2.2 Historical En Route towards Oral Diabetic Medication

3. Treatments Available for Diabetes Mellitus

  • 3.1 Non-Pharmacological Approaches for Diabetes Mellitus
  • 3.2 Pharmacological Approaches for Diabetes Mellitus

4. Cataloguing of Antidiabetic Agents

  • 4.1 Antidiabetic: Oral Agents
    • 4.1.1 Biguanides
    • 4.1.2 Thiazolidinediones (TZDs)
    • 4.1.3 Sulfonylureas
    • 4.1.4 Meglitinides
    • 4.1.5 α- Glucosidase Inhibitors
    • 4.1.6 Dipeptidyl Peptidase-4 Inhibitor
    • 4.1.7 Bile Acid Sequestrants (BAS)
    • 4.1.8 Dopamine Agonist-2

5. Antidiabetic: Injectable Drugs

  • 5.1 Insulin: A life saving Modality
  • 5.2 Non-Insulin Alternatives for Diabetes Mellitus

6. US Diabetes Epidemiology

  • 6.1 Prevalence of Type 1 & 2 Diabetes
  • 6.2 Economic Burden Associated with Type 1 & 2 Diabetes: Productivity Loss & Medical Bills

7. US Antidiabetics Market Overview

  • 7.1 Antidiabetic Injectable Market Trends in US
  • 7.2 Antidiabetic Oral Drugs Market Trends in US
  • 7.3 Commending Trends of Antidiabetics

8. US: Key Marketed Antidiabetic Drugs

  • 8.1 Insulin Degludec (Tresiba)- Injection
  • 8.2 Insulin Lispro - Injection
  • 8.3 Insulin Inhalation(Afrezza) - Inhalation
  • 8.4 Insulin Glargine (Toujeo) - Injection
  • 8.5 Insulin Glulisine (Apidra) - Injection
  • 8.6 Insulin Aspart (NovoLog) - Injection
  • 8.7 Insulin Detemir (Levemir FlexTouch) - Injection
  • 8.8 Insulin Glargine (Lantus) - Injection
  • 8.9 Insulin Aspart/Insulin Protamine Aspart (NovoLog) - Injection

9. US Biosimilar Market: Glargine Basaglar - The First "Biosimilar" Insulin

  • 9.1 Overview
  • 9.2 Impact of Biosimilar Insulin

10. US Antidiabetics Drug Market Dynamics

  • 10.1 Accelerative Parameters
  • 10.2 Major Challenges

11. US Antidiabetics Drug Market Future Prospects

12. Competitive Landscape

  • 12.1 AstraZeneca
  • 12.2 Bayer
  • 12.3 Boehringer Ingelheim
  • 12.4 Eli-Lilly
  • 12.5 Johnson & Johnson
  • 12.6 Merck
  • 12.7 Novartis
  • 12.8 Novo Nordisk
  • 12.9 Sanofi
  • 12.10 Takeda

List of Figures

  • Figure 1-1: Illustration of the Categories of Diabetes Mellitus
  • Figure 1-2: Percentage of Different types of Antidiabetics Used
  • Figure 2-1: Historical Pathway of oral Diabetic Medication
  • Figure 3-1: Control of Glucose Uptake during Muscle Working
  • Figure 4-1: Categorization of Oral Antidiabetics Approved in US
  • Figure 4-2: Chemical Structure of Metformin, Phenformin & Buformin
  • Figure 4-3: Illustration of the Sub-Categories of Sulfonylureas
  • Figure 5-1: Mechanism of Insulin in Regulation of Blood Glucose Levels
  • Figure 5-2: Differences between Diabetes Mellitus 1 & 2 over Insulin
  • Figure 5-3: Structure of Differentiation of Peptidic Insulin Analogs
  • Figure 5-4: Demonstration of Action Profiles of Insulin Analogue
  • Figure 5-5: Activity Profiles of Different Types of Insulin
  • Figure 5-6: Difference between Lantus & Levemir
  • Figure 6-1: US: Number of Type 1 Diabetes Incidence (Million), 2016 & 2022
  • Figure 6-2: US: Number of Type 2 Diabetes Incidence (Million), 2014 - 2022
  • Figure 6-3: US: Type 1 Diabetes Prevalence Rate (%), 2016 & 2022
  • Figure 6-4: US: Type 2 Diabetes Prevalence Rate (%), 2014 - 2022
  • Figure 6-5: US: Diabetes Prevalence Rate among Adults Aged 18+ (%), 2010 - 2016
  • Figure 6-6: US: Obesity Rate Among Adults Aged 18+ (%), 2010 - 2016
  • Figure 6-7: US: Percentage of Adults with Obesity by State (%), 2015
  • Figure 6-8: Illustration of Total Cost of Diabetes Expenditure
  • Figure 6-9: Annual Average Cost Of Diabetes per Person in US
  • Figure 6-10: US: Productivity Loss Due To Type 1 Diabetes (US$ Billion), 2014 - 2022
  • Figure 6-11: US: Productivity Loss Due To Type 2 Diabetes (US$ Billion), 2014 - 2022
  • Figure 6-12: US: Medical Cost for Type 1 Diabetes (US$ Billion), 2014-2022
  • Figure 6-13: US: Medical Cost for Type 2 Diabetes (US$ Billion), 2014-2022
  • Figure 7-1: Overview of Diabetic Drug Market Segmentation
  • Figure 7-2: US: Antidiabetics Drug Market (US$ Billion), 2014 - 2022
  • Figure 7-3: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US$ Billion), 2016
  • Figure 7-4: US - Percentage of Most Common Class of Antidiabetics Drugs
  • Figure 7-5: US - Percentage of Generally Prescribed Anti-Diabetic Drugs (%)
  • Figure 8-1: US - Insulin Degludec (Tresiba) Injection Sales (US$ Million), 2016-2022
  • Figure 8-2: US -Insulin Lispro Injection Sales (US$ Million), 2016-2022
  • Figure 8-3: US - Insulin Glargine (Toujeo) Injection Sales (US$ Million), 2016-2022
  • Figure 8-4: US - Insulin Glulisine (Apidra) Injection Sales (US$ Million), 2016-2022
  • Figure 8-5: US - Insulin Detemir (Levemir FlexTouch) Injection Sales (US$ Million), 2016-2022
  • Figure 9-1: Major Accelerative Parameters for Antidiabetic Market in US
  • Figure 9-2: Estimated Impact of Increasing Trend in Obesity by 2020
  • Figure 9-3: Estimated Increase in Total Number with Diagnosed Diabetes till 2050
  • Figure 9-4: Major challenges in Antidiabetics Market
  • Figure 9-5: Important Challenges with the Use of Insulin
  • Figure 10-1: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US$ Billion), 2022
  • Figure 10-2: Illustration of Antidiabetic Drugs Under Development
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.